News

The FDA approved ViiV Healthcare's Tivicay PD for children weighing at least 2 kg, making it the first second-generation HIV integrase inhibitor for this group.

Tevimbra plus Ziihera with chemo raises survival in first-line HER2-positive gastroesophageal cancer, offering a new FDA-approved option.

Rasonque (daraxonrasib) was approved more than six months ahead of its PDUFA date. It has a wholesale acquisition cost of $39,800 for a 30-day supply.

How the USPS financial crisis changes the conversation about healthcare communication and mailing.

Stem cell transplants from younger, more mismatched unrelated donors showed favorable one-year outcomes in a new ACCESS trial analysis.

Over three years, Advocate Health Care is investing $1 billion in health and wellness initiatives in Chicago, including building a new hospital, expanded outpatient services and new workforce development initiatives.

Aon projects a fourth straight year of near double-digit health cost growth for U.S. employers, with 2027 costs set to top $19,000 per worker.

The subcutaneous version of Leqembi has a wholesale acquisition cost of $770 weekly.

Oregon Health & Science University researchers found sensitive caregiving in infancy can offset ADHD risk linked to higher maternal inflammation in pregnancy, a new study shows.

A deficiency in the hormone GDF15 correlates with liver damage biomarkers, suggesting the hormone may protect against MASH progression and offer a new therapeutic target.

HIV medication adherence rose after SNAP payments and fell nearly 12 points by the end of the benefit cycle, according to a new study of Philadelphia SNAP beneficiaries.

Genglycos is a one-time infusion to replace the G6PC gene in patients with glycogen storage disease type Ia, a rare genetic disorder. It will have a wholesale acquisition cost of $2.7 million per patient.

Pasatru is approved to treat adults with fibrodysplasia ossificans progressiva (FOP). It will have an annual list pricing range at launch of $693,000 to $2.1 million, depending on dose and patient weight.

Medicaid expansion was linked to improved insurance coverage, earlier diagnosis, and better survival for NSCLC patients, especially in underserved areas.

Cleveland Clinic and Siemens Healthineers signed a 10-year deal to expand imaging, cancer care and staff training.

The results of an Australian mouse-model-based study show that the bladder nerves that detect urinary tract infections may drive the urinary urgency that helps clear infection.

A Brukinsa access program for CLL patients in low- and middle-income countries has been extended through 2028, aiming to reach about 1,000 patients.

Researchers of a systematic review and meta-analysis said there is a need for metabolic and hepatic assessment regardless of weight.

Tiffany Phung, Pharm.D., CSP, of UC Davis Health, discusses an alternative approach to clinical research and practice improvement ahead of HSES 2026.

Additionally, a majority of those surveyed by the law firm DLA Piper were worried about future access to their medications.

A new study found cannabis use was linked to more falls in older adults with HIV, though cigarette smoking explained most of the risk.

The FDA approved a Lerochol autoinjector and updated its label to reflect a lower risk of major cardiovascular events.

Line-field confocal optical coherence tomography (LC-OCT) and reflectance confocal microscopy (RCM) have good specificity and sensitivity. Cost may be an issue.

A draft ICER report found that baxdrostat and lorundrostat don't lower blood pressure more than older generics but do cost much more.

The REAL Health Providers Act and the CMS National Provider Directory (NPD) initiative will to reshape how provider data is collected, maintained, and enforced.

Healthcare journalist Ken Terry’s new book proposes a subscription-based primary care system as a free-market alternative to Medicare for All.

Will Carroll, Pharm.D., chief pharmacy officer at Sutter Health, discusses strategic priorities and his vision for specialty pharmacy growth.

Perry Cohen, Pharm.D., speaks with Dipak Patel, CEO of Globo, about communication in healthcare, particuarly translation services.